Demonstration of Interferon-α Receptors in Cultured Cell Lines and in Myeloid Cells from Patients with Acute or Chronic Myeloid Leukemia

1988 ◽  
pp. 57-62
Author(s):  
B. Möller ◽  
A. Neubauer ◽  
W. Siegert ◽  
D. Huhn
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Cell Lines ◽  
Myeloid Leukemia ◽  
Myeloid Cells ◽  
Interferon Α ◽  
Cultured Cell

scholarly journals Tyrosine kinase inhibitors and interferon‐α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines

2020 ◽  
Vol 34 (3) ◽  
pp. 3773-3791 ◽  
Author(s):  
Maria Omsland ◽  
Vibeke Andresen ◽  
Stein‐Erik Gullaksen ◽  
Pilar Ayuda‐Durán ◽  
Mihaela Popa ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Cell Lines ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Interferon Α ◽  
Tunneling Nanotube

scholarly journals Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib

Glycobiology ◽  
2015 ◽  
Vol 26 (4) ◽  
pp. 343-352 ◽  
Author(s):  
Silvina Laura Lompardía ◽  
Mariángeles Díaz ◽  
Daniela Laura Papademetrio ◽  
Marilina Mascaró ◽  
Matías Pibuel ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Cell Lines ◽  
Myeloid Leukemia ◽  
Leukemia Cell ◽  
Chronic Myeloid Leukemia Cell ◽  
Leukemia Cell Lines ◽  
Myeloid Leukemia Cell

scholarly journals High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-α

2003 ◽  
Vol 72 (3) ◽  
pp. 170-176 ◽  
Author(s):  
J.L. Steegmann ◽  
M.J. Requena ◽  
P. Martín-Regueira ◽  
R. de la Cámara ◽  
F. Casado ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Interferon Α ◽  
High Incidence

scholarly journals Differential Regulation of Telomeric Complex by BCR-ABL1 Kinase in Human Cellular Models of Chronic Myeloid Leukemia—From Single Cell Analysis to Next-Generation Sequencing

Genes ◽  
2020 ◽  
Vol 11 (10) ◽  
pp. 1145
Author(s):  
Anna Deregowska ◽  
Monika Pepek ◽  
Katarzyna Pruszczyk ◽  
Marcin M. Machnicki ◽  
Maciej Wnuk ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Chronic Myeloid Leukemia ◽  
Telomere Length ◽  
Cell Lines ◽  
Copy Number ◽  
Myeloid Leukemia ◽  
Telomere Maintenance ◽  
Next Generation ◽  
Cellular Models ◽  
Generation Sequencing

Telomeres are specialized nucleoprotein complexes, localized at the physical ends of chromosomes, that contribute to the maintenance of genome stability. One of the features of chronic myeloid leukemia (CML) cells is a reduction in telomere length which may result in increased genomic instability and progression of the disease. Aberrant telomere maintenance in CML is not fully understood and other mechanisms such as the alternative lengthening of telomeres (ALT) are involved. In this work, we employed five BCR-ABL1-positive cell lines, namely K562, KU-812, LAMA-84, MEG-A2, and MOLM-1, commonly used in the laboratories to study the link between mutation, copy number, and expression of telomere maintenance genes with the expression, copy number, and activity of BCR-ABL1. Our results demonstrated that the copy number and expression of BCR-ABL1 are crucial for telomere lengthening. We observed a correlation between BCR-ABL1 expression and telomere length as well as shelterins upregulation. Next-generation sequencing revealed pathogenic variants and copy number alterations in major tumor suppressors, such as TP53 and CDKN2A, but not in telomere-associated genes. Taken together, we showed that BCR-ABL1 kinase expression and activity play a crucial role in the maintenance of telomeres in CML cell lines. Our results may help to validate and properly interpret results obtained by many laboratories employing these in vitro models of CML.

scholarly journals All-trans retinoic acid potentiates the inhibitory effects of interferon α on chronic myeloid leukemia progenitors in vitro

Leukemia ◽  
1997 ◽  
Vol 11 (5) ◽  
pp. 667-673 ◽  
Author(s):  
FX Mahon ◽  
H Chahine ◽  
C Barbot ◽  
V Pigeonnier ◽  
B Jazwiec ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Interferon Α ◽  
Inhibitory Effects ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

scholarly journals Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

Leukemia ◽  
2009 ◽  
Vol 23 (11) ◽  
pp. 1999-2006 ◽  
Author(s):  
A Davies ◽  
N E Jordanides ◽  
A Giannoudis ◽  
C M Lucas ◽  
S Hatziieremia ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Cell Lines ◽  
Myeloid Leukemia ◽  
Drug Transporters ◽  
Leukemia Cells ◽  
Active Uptake ◽  
Major Drug

scholarly journals Interferon-α modulates the immune response enhancing B7-1 and B7-2 costimulatory molecules and T8 lymphocytes in chronic myeloid leukemia

Leukemia ◽  
2003 ◽  
Vol 17 (5) ◽  
pp. 983-984 ◽  
Author(s):  
C Delfini ◽  
F Centis ◽  
L Tabellini ◽  
G Nicolini ◽  
G Visani
Keyword(s):  
Immune Response ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Costimulatory Molecules ◽  
Interferon Α

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

2011 ◽  
Vol 52 (11) ◽  
pp. 2139-2147 ◽  
Author(s):  
Carine Tang ◽  
Lisa Schafranek ◽  
Dale B. Watkins ◽  
Wendy T. Parker ◽  
Sarah Moore ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Lines ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Leukemia Cell ◽  
Leukemia Cell Lines ◽  
Inhibitor Resistance ◽  
Myeloid Leukemia Cell

scholarly journals Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets

Leukemia ◽  
2020 ◽  
Author(s):  
Shady Adnan-Awad ◽  
Daehong Kim ◽  
Helena Hohtari ◽  
Komal Kumar Javarappa ◽  
Tania Brandstoetter ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Signaling Pathways ◽  
Cell Lines ◽  
Myeloid Leukemia ◽  
Drug Sensitivity ◽  
Lymphoblastic Leukemia ◽  
High Risk Patient ◽  
Therapeutic Targets ◽  
Hematopoietic Progenitor Cell ◽  
Sensitivity Testing

Abstract The oncogenic protein Bcr-Abl has two major isoforms, p190Bcr-Abl and p210Bcr-Abl. While p210Bcr-Abl is the hallmark of chronic myeloid leukemia (CML), p190Bcr-Abl occurs in the majority of Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) patients. In CML, p190Bcr-Abl occurs in a minority of patients associating with distinct hematological features and inferior outcomes, yet the pathogenic role of p190Bcr-Abl and potential targeting therapies are largely uncharacterized. We employed next generation sequencing, phospho-proteomic profiling, and drug sensitivity testing to characterize p190Bcr-Abl in CML and hematopoietic progenitor cell line models (Ba/f3 and HPC-LSK). p190Bcr-Abl CML patients demonstrated poor response to imatinib and frequent mutations in epigenetic modifiers genes. In contrast with p210Bcr-Abl, p190Bcr-Abl exhibited specific transcriptional upregulation of interferon, interleukin-1 receptor, and P53 signaling pathways, associated with hyperphosphorylation of relevant signaling molecules including JAK1/STAT1 and PAK1 in addition to Src hyperphosphorylation. Comparable to p190Bcr-Abl CML patients, p190Bcr-Abl cell lines demonstrated similar transcriptional and phospho-signaling signatures. With the drug sensitivity screening we identified targeted drugs with specific activity in p190Bcr-Abl cell lines including IAP-, PAK1-, and Src inhibitors and glucocorticoids. Our results provide novel insights into the mechanisms underlying the distinct features of p190Bcr-Abl CML and promising therapeutic targets for this high-risk patient group.

Sign in / Sign up

Export Citation Format

Share Document